propagermanium has been researched along with Breast Cancer in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hayashi, N; Jomori, T; Kitagawa, D; Kogawa, T; Masuda, T; Mimori, K; Nakanishi, Y; Nakayama, KI; Noda, M; Ohno, S | 1 |
1 trial(s) available for propagermanium and Breast Cancer
| Article | Year |
|---|---|
Phase I dose-escalation trial to repurpose propagermanium, an oral CCL2 inhibitor, in patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Chemokine CCL2; F-Box-WD Repeat-Containing Protein 7; Female; Germanium; Humans; Interleukin-6; Japan; Macrophages; Middle Aged; Myeloid-Derived Suppressor Cells; Organometallic Compounds; Propionates; RNA, Messenger; Signal Transduction; Young Adult | 2020 |